Literature DB >> 26298430

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Keith L Knutson1,2, Matthew J Maurer3, Claudia C Preston4, Kirsten B Moysich5, Krista Goergen3, Kieran M Hawthorne3, Julie M Cunningham6, Kunle Odunsi5, Lynn C Hartmann7, Kimberly R Kalli7, Ann L Oberg3, Ellen L Goode8.   

Abstract

The immune system constitutes one of the host factors modifying outcomes in ovarian cancer. Regulatory T cells (Tregs) are believed to be a major factor in preventing the immune response from destroying ovarian cancers. Understanding mechanisms that regulate Tregs in the tumor microenvironment could lead to the identification of novel targets aimed at reducing their influence. In this study, we used immunofluorescence-based microscopy to enumerate Tregs, total CD4 T cells, and CD8(+) cytotoxic T cells in fresh frozen tumors from over 400 patients with ovarian cancer (>80 % high-grade serous). We sought to determine whether Tregs were associated with survival and genetic variation in 79 genes known to influence Treg induction, trafficking, or function. We used Cox regression, accounting for known prognostic factors, to estimate hazard ratios (HRs) associated with T cell counts and ratios. We found that the ratios of CD8 T cells and total CD4 T cells to Tregs were associated with improved overall survival (CD8/Treg HR 0.84, p = 0.0089; CD4/Treg HR 0.88, p = 0.046) and with genetic variation in IL-10 (p = 0.0073 and 0.01, respectively). In multivariate analyses, the associations between the ratios and overall survival remained similar (IL-10 and clinical covariate-adjusted CD8/Treg HR 0.85, p = 0.031; CD4/Treg HR 0.87, p = 0.093), suggesting that this association was not driven by variation in IL-10. Thus, integration of novel tumor phenotyping measures with extensive clinical and genetic information suggests that the ratio of T cells to Tregs may be prognostic of outcome in ovarian cancer, regardless of inherited genotype in genes related to Tregs.

Entities:  

Keywords:  CD8; Immune suppression; Treg; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 26298430      PMCID: PMC4651184          DOI: 10.1007/s00262-015-1753-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  52 in total

1.  Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Bobbie S Gostout; Monica B Jones; C Robert Stanhope; Timothy O Wilson; Karl C Podratz; William A Cliby
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

2.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

Review 3.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

4.  Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.

Authors:  Andrew G Jarnicki; Joanne Lysaght; Stephen Todryk; Kingston H G Mills
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

5.  CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.

Authors:  Rongcun Yang; Zhong Cai; Yuan Zhang; William H Yutzy; Katherine F Roby; Richard B S Roden
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

6.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

7.  IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Authors:  Keith L Knutson; Yushe Dang; Hailing Lu; Jason Lukas; Bond Almand; Ekram Gad; Ehizoje Azeke; Mary L Disis
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

8.  Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.

Authors:  Federica Meloni; Monica Morosini; Nadia Solari; Ileana Passadore; Caterina Nascimbene; Monique Novo; Marco Ferrari; Marco Cosentino; Franca Marino; Ernesto Pozzi; Anna M Fietta
Journal:  Hum Immunol       Date:  2006-03-31       Impact factor: 2.850

9.  Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Authors:  Thorsten Hagemann; Julia Wilson; Frances Burke; Hagen Kulbe; Ninfeng Fiona Li; Annette Plüddemann; Kellie Charles; Siamon Gordon; Frances R Balkwill
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

10.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

Authors:  Jennifer Permuth-Wey; Kate Lawrenson; Howard C Shen; Aneliya Velkova; Jonathan P Tyrer; Zhihua Chen; Hui-Yi Lin; Y Ann Chen; Ya-Yu Tsai; Xiaotao Qu; Susan J Ramus; Rod Karevan; Janet Lee; Nathan Lee; Melissa C Larson; Katja K Aben; Hoda Anton-Culver; Natalia Antonenkova; Antonis C Antoniou; Sebastian M Armasu; François Bacot; Laura Baglietto; Elisa V Bandera; Jill Barnholtz-Sloan; Matthias W Beckmann; Michael J Birrer; Greg Bloom; Natalia Bogdanova; Louise A Brinton; Angela Brooks-Wilson; Robert Brown; Ralf Butzow; Qiuyin Cai; Ian Campbell; Jenny Chang-Claude; Stephen Chanock; Georgia Chenevix-Trench; Jin Q Cheng; Mine S Cicek; Gerhard A Coetzee; Linda S Cook; Fergus J Couch; Daniel W Cramer; Julie M Cunningham; Agnieszka Dansonka-Mieszkowska; Evelyn Despierre; Jennifer A Doherty; Thilo Dörk; Andreas du Bois; Matthias Dürst; Douglas F Easton; Diana Eccles; Robert Edwards; Arif B Ekici; Peter A Fasching; David A Fenstermacher; James M Flanagan; Montserrat Garcia-Closas; Aleksandra Gentry-Maharaj; Graham G Giles; Rosalind M Glasspool; Jesus Gonzalez-Bosquet; Marc T Goodman; Martin Gore; Bohdan Górski; Jacek Gronwald; Per Hall; Mari K Halle; Philipp Harter; Florian Heitz; Peter Hillemanns; Maureen Hoatlin; Claus K Høgdall; Estrid Høgdall; Satoyo Hosono; Anna Jakubowska; Allan Jensen; Heather Jim; Kimberly R Kalli; Beth Y Karlan; Stanley B Kaye; Linda E Kelemen; Lambertus A Kiemeney; Fumitaka Kikkawa; Gottfried E Konecny; Camilla Krakstad; Susanne Krüger Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Sandrina Lambrechts; Johnathan M Lancaster; Nhu D Le; Arto Leminen; Douglas A Levine; Dong Liang; Boon Kiong Lim; Jie Lin; Jolanta Lissowska; Karen H Lu; Jan Lubiński; Galina Lurie; Leon F A G Massuger; Keitaro Matsuo; Valerie McGuire; John R McLaughlin; Usha Menon; Francesmary Modugno; Kirsten B Moysich; Toru Nakanishi; Steven A Narod; Lotte Nedergaard; Roberta B Ness; Heli Nevanlinna; Stefan Nickels; Houtan Noushmehr; Kunle Odunsi; Sara H Olson; Irene Orlow; James Paul; Celeste L Pearce; Tanja Pejovic; Liisa M Pelttari; Malcolm C Pike; Elizabeth M Poole; Paola Raska; Stefan P Renner; Harvey A Risch; Lorna Rodriguez-Rodriguez; Mary Anne Rossing; Anja Rudolph; Ingo B Runnebaum; Iwona K Rzepecka; Helga B Salvesen; Ira Schwaab; Gianluca Severi; Viji Shridhar; Xiao-Ou Shu; Yurii B Shvetsov; Weiva Sieh; Honglin Song; Melissa C Southey; Beata Spiewankiewicz; Daniel Stram; Rebecca Sutphen; Soo-Hwang Teo; Kathryn L Terry; Daniel C Tessier; Pamela J Thompson; Shelley S Tworoger; Anne M van Altena; Ignace Vergote; Robert A Vierkant; Daniel Vincent; Allison F Vitonis; Shan Wang-Gohrke; Rachel Palmieri Weber; Nicolas Wentzensen; Alice S Whittemore; Elisabeth Wik; Lynne R Wilkens; Boris Winterhoff; Yin Ling Woo; Anna H Wu; Yong-Bing Xiang; Hannah P Yang; Wei Zheng; Argyrios Ziogas; Famida Zulkifli; Catherine M Phelan; Edwin Iversen; Joellen M Schildkraut; Andrew Berchuck; Brooke L Fridley; Ellen L Goode; Paul D P Pharoah; Alvaro N A Monteiro; Thomas A Sellers; Simon A Gayther
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  21 in total

1.  Transcription factor FOXP3 gene variants affect epithelial ovarian carcinoma in the Han Chinese population.

Authors:  Yan Zhang; Lian Xu; Bin Zhou; Qin Li; Di You; Chenlu Liu; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Xingming Huang; Mingwei Yuan; Zhu Lan; Wei Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.

Authors:  Sofya Marchenko; Iris Piwonski; Inga Hoffmann; Bruno Valentin Sinn; Catarina Alisa Kunze; Nanna Monjé; Jonathan Pohl; Hagen Kulbe; Wolfgang Daniel Schmitt; Sylvia Darb-Esfahani; Elena Ioana Braicu; Ann-Christin von Brünneck; Jalid Sehouli; Carsten Denkert; David Horst; Korinna Jöhrens; Eliane Tabea Taube
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-28       Impact factor: 4.553

3.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

4.  The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report.

Authors:  Rikki A Cannioto; Lara E Sucheston-Campbell; Shalaka Hampras; Ellen L Goode; Keith Knutson; Roberta Ness; Francesmary Modugno; Paul Wallace; J Brian Szender; Paul Mayor; Chi-Chen Hong; Janine M Joseph; Grace Friel; Warren Davis; Mary Nesline; Kevin H Eng; Robert P Edwards; Bridget Kruszka; Kristina Schmitt; Kunle Odunsi; Kirsten B Moysich
Journal:  Int J Gynecol Cancer       Date:  2017-01       Impact factor: 3.437

5.  PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.

Authors:  Lavakumar Karyampudi; Purushottam Lamichhane; James Krempski; Kimberly R Kalli; Marshall D Behrens; Doris M Vargas; Lynn C Hartmann; Jo Marie T Janco; Haidong Dong; Karen E Hedin; Allan B Dietz; Ellen L Goode; Keith L Knutson
Journal:  Cancer Res       Date:  2015-11-13       Impact factor: 12.701

Review 6.  Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Fuhai Li; Stephen S T Wong; Samuel C Mok
Journal:  Biomolecules       Date:  2016-01-06

7.  TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment.

Authors:  Meng Wu; Xian Chen; Jianfang Lou; Shuping Zhang; Xiaojie Zhang; Lei Huang; Ruihong Sun; Peijun Huang; Fang Wang; Shiyang Pan
Journal:  Oncotarget       Date:  2016-07-12

8.  APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Authors:  Brandon Leonard; Gabriel J Starrett; Matthew J Maurer; Ann L Oberg; Mieke Van Bockstal; Jo Van Dorpe; Olivier De Wever; Jozien Helleman; Anieta M Sieuwerts; Els M J J Berns; John W M Martens; Brett D Anderson; William L Brown; Kimberly R Kalli; Scott H Kaufmann; Reuben S Harris
Journal:  Clin Cancer Res       Date:  2016-03-25       Impact factor: 12.531

Review 9.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 10.  CAR-T cell therapy in ovarian cancer: from the bench to the bedside.

Authors:  Xinxin Zhu; Han Cai; Ling Zhao; Li Ning; Jinghe Lang
Journal:  Oncotarget       Date:  2017-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.